A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects
Public ClinicalTrials.gov record NCT07671833. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of LY03015 in Healthy Chinese and Caucasian Adult Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, single-dose, parallel-group study to evaluate the safety, tolerability and pharmacokinetic characteristics of LY03015 in healthy Chinese and Caucasian adult subjects. The duration of study will be around up to 42 days for each participant, including up to 14 days of screening period, baseline visit, and a 28-day safety assessment period with a 7-day/6-night stay in the clinical research unit.
Study identification
- NCT ID
- NCT07671833
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 24 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 45 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 14, 2026
- Primary completion
- May 7, 2026
- Completion
- May 26, 2026
- Last update posted
- Jun 25, 2026
2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Collaborative Neuroscience Research, LLC. | Los Alamitos | California | 90720 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Healthy Participants trials
Other public records listing Healthy Participants. Sorted by last update posted; newest first. Not a recommendation.
- NCT07751250: Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function Recruiting
- NCT07780383: A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration Not yet recruiting
- NCT07219719: Temporal Interference for Thalamocortical Activity and Network Modulation Recruiting
- NCT07753252: Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body Not yet recruiting
- NCT07746167: Pupillary Dilation Reflex in Healthy Volunteers Recruiting
- NCT07745907: A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07671833, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 25, 2026 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07671833 live on ClinicalTrials.gov.